Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence

Background and objectives: alemtuzumab is a monoclonal anti-CD52 antibody acting on B and T cells in highly active multiple sclerosis (MS). We analyzed changes in lymphocyte subsets after alemtuzumab administration in relation to disease activity and autoimmune adverse events. Methods: lymphocyte su...

Descripción completa

Detalles Bibliográficos
Autores principales: Signoriello, Elisabetta, Lus, Giacomo, Saccà, Francesco, Puthenparampil, Marco, Coppola, Cinzia, Di Pietro, Andrea, Puoti, Gianfranco, Criscuolo, Maria Cristina, Foschi, Matteo, Miele, Giuseppina, Abbadessa, Gianmarco, Brescia Morra, Vincenzo, Gallo, Paolo, Bonavita, Simona, Sormani, Maria Pia, Signori, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002781/
https://www.ncbi.nlm.nih.gov/pubmed/36902555
http://dx.doi.org/10.3390/jcm12051768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002781/
https://www.ncbi.nlm.nih.gov/pubmed/36902555
http://dx.doi.org/10.3390/jcm12051768

Ejemplares similares